Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

Ferrara, Napoleone; Hillan, Kenneth J.; Novotny, William

doi:10.1016/j.bbrc.2005.05.132

Cited by 867 publications

(614 citation statements)

References 73 publications

Supporting

Mentioning

596

Contrasting

Unclassified

Order By: Relevance

“…VEGF/VEGF receptor pathway represents a key player in tumor-induced angiogenesis and, consequently, tumor progression and metastasis. The humanized anti-VEGF monoclonal antibody bevacizumab has been recently approved for cancer treatment and results are encouraging even if not untroubled (23,24). Endocannabinoids warrant further investigation since they have been clearly shown to interfere with the VEGF pathway in different systems and may provide a useful tool to target VEGF in cancer.…”

Section: Discussionmentioning

confidence: 99%

Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review)

Bifulco

Laezza²,

Gazzerro

et al. 2007

Oncol Rep

View full text Add to dashboard Cite

Abstract. The medicinal properties of extracts from the hemp plant Cannabis sativa have been known for centuries but only in the 90s membrane receptors for the Cannabis major principle were discovered in mammalian cells. Later on the endogenous ligands for the cannabinoid receptors were identified and the term 'endocannabinoid system' was coined to indicate the complex signaling system of cannabinoid receptors, endogenous ligands and the enzymes responsible for their biosynthesis and inactivation. The 'endocannabinoid system' is involved in a broad range of functions and in a growing number of pathological conditions. There is increasing evidence that endocannabinoids are able to inhibit cancer cell growth in culture as well as in animal models. Most work has focused on the role of endocannabinoids in regulating tumor cell growth and apoptosis and ongoing research is addressed to further dissect the precise mechanisms of cannabinoid antitumor action. However, endocannabinoids are now emerging as suppressors of angiogenesis and tumor spreading since they have been reported to inhibit angiogenesis, cell migration and metastasis in different types of cancer, pointing to a potential role of the endocannabinoid system as a target for a therapeutic approach of such malignant diseases. The potential use of cannabinoids to retard tumor growth and spreading is even more appealing considering that they show a good safety profile, regarding toxicity, and are already used in cancer patients as palliatives to stimulate appetite and to prevent devastating effects such as nausea, vomiting and pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review)

Bifulco

Laezza²,

Gazzerro

et al. 2007

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…147,148 For instance, the antibody bevacizumab (Avastin) targets VEGF-A to inhibit angiogenesis in metastatic cancers. 149 In addition, soluble decoy receptors can act as "VEGF-Traps" to suppress tumor growth and vascularization. 150 Kinase blockers, including sunitinib malate (Sutent), can directly target Vegfr2 to inhibit its kinase activity.…”

Section: Src and Downstream Chemotherapeutic Targetsmentioning

confidence: 99%

Src Points the Way to Biomarkers and Chemotherapeutic Targets

Krishnan¹,

Miller

Goldberg³

2012

Genes & Cancer

View full text Add to dashboard Cite

The role of Src in tumorigenesis has been extensively studied since the work of Peyton Rous over a hundred years ago. Src is a non-receptor tyrosine kinase that plays key roles in signaling pathways controlling tumor cell growth and migration. Src regulates the activities of numerous molecules to induce cell transformation. However, transformed cells do not always migrate and realize their tumorigenic potential. They can be normalized by surrounding nontransformed cells by a process called contact normalization. Tumor cells need to override contact normalization to become malignant or metastatic. In this review, we discuss the role of Src in cell migration and contact normalization, with emphasis on Cas and Abl pathways. This paradigm illuminates several chemotherapeutic targets and may lead to the identification of new biomarkers and the development of effective anticancer treatments.

show abstract

“…Bevacizumab O Bevacizumab (Avastin ® ; Genentech, Inc, San Francisco, Califórnia, USA) é um anticorpo monoclonal humanizado contra todas as isoformas de VEGF (37)(38) . Esta substância foi desenvolvida e recebeu aprovação do FDA (fevereiro, 2004) para ser utilizada por via intravenosa no tratamento do câncer cólon-retal metastático (39) .…”

Section: Agentes Antivegfunclassified

Antiangiogênicos no glaucoma

Lucena¹,

Yamane²

2008

Rev. bras.oftalmol.

View full text Add to dashboard Cite

RESUMOA angiogênese é um processo complexo que resulta na formação de novos vasos sangüíneos. Ocorre tanto em situações fisiológicas quanto patológicas e está envolvida com várias patologias oculares. Dentre os mediadores químicos da angiogênese, o fator de crescimento do endotélio vascular (VEGF) é reconhecido como um dos mais importantes. Nos últimos anos, agentes antiVEGF foram introduzidos para o tratamento de neovascularizações do segmento posterior com resultados muito positivos. Alguns autores demonstraram benefícios do uso dessas substâncias no controle do glaucoma em situações específicas.

show abstract

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

Cited by 867 publications

References 73 publications

Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review)

Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review)

Src Points the Way to Biomarkers and Chemotherapeutic Targets

Antiangiogênicos no glaucoma

Contact Info

Product

Resources

About